ERBB2 and breast carcinoma: In a mouse model mimicking breast cancer metastasized to bone, HER2-TTC inhibited tumor growth and tumor-induced abnormal bone growth in vivo via its dual mode of action of HER2 binding and the bone-seeking properties of the radioactive decay product, radium-223.